Skip to main content

Table 4 Predictors of PFS

From: Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis

 

Univariable

Multivariable

HR

95% CI

p-value

aHR

95% CI

p-value

Age > 60 yr

0.72

0.56–0.99

0.046

   

Male

0.81

0.52–1.27

0.364

   

PIVKA II > 250 mAU/mL

1.30

0.97–1.75

0.080

   

AFP > 200 ng/mL

1.85

1.39–2.47

 < 0.001

1.79

1.33–2.40

 < 0.001

Total bilirubin

1.08

1.00–1.17

0.063

   

Albumin

1.03

0.80–1.34

0.798

   

ALT

1.00

1.00–1.01

0.129

   

AST

1.00

1.00–1.00

0.183

   

PT

1.48

0.92–2.39

0.109

   

Presence of ascites

1.23

0.89–1.69

0.212

   

ECOG 1 (vs 0)

1.70

1.25–2.33

0.001

1.61

1.18–2.21

0.003

Child B,C (vs A)

1.18

0.85–1.65

0.330

   

BCLC stage C,D (vs B)

1.35

0.85–2.14

0.209

   

Tumor size

1.00

1.00–1.00

0.060

   

Extrahepatic metastasis

1.10

0.81–1.49

0.559

   

Portal vein thrombosis

1.07

0.81–1.43

0.626

   

Biliary invasion

1.34

0.76–2.36

0.307

   

Lenvatinib (vs sorafenib)

0.73

0.52–1.04

0.078

0.77

0.55–1.11

0.159

Previous anti-HCC treatment

0.84

0.58–1.22

0.356

   
  1. Multivariable analysis was performed using variables with p value under 0.05 at univariable analysis
  2. HR, hazard ratio; aHR, adjusted hazard ratio; CI, confidence interval; PIVKA, protein induced by vitamin K absence or antagonists-II; AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; ECOG, Eastern Cooperative Oncology Group; BCLC, Barcelona Clinic Liver Cancer
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us